Compare Neurocrine Biosciences Inc (NBIX) vs Invesco Solar ETF (TAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Invesco Solar ETF — how do they compare? Neurocrine Biosciences Inc trades at $179 (market cap $17.40B), while Invesco Solar ETF trades at $53.51. The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Invesco Solar ETF nearer its low. Which is the better fit depends on your goals.
| NBIX | TAN | |
|---|---|---|
Market Cap | $17.40B | — |
Sector | Health | Sector/Thematic |
52-Week High | $180.55 | $73.95 |
52-Week Low | $123.10 | $36.07 |
Enterprise Value | $16.49B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $173.00, up 1.24% today, with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with Q1 2026 EPS of $1.94 beating expectations by 59%, revenue growth to $3.1B in 2026, and net income margin expanding to 21.55%. Recent news highlights executive appointments and positive clinical trial updates for crinecerfont, supporting growth prospects.
Outlook remains positive with 86% analyst buy ratings and a $196.08 consensus price target implying 13% upside. Key risks include execution of pipeline developments and integration of acquisitions. The stock's valuation at P/E 26.62 appears reasonable given earnings growth trajectory and strong profitability metrics.
TAN trades at $52.69, down 2.24% amid broad market weakness, with technical indicators signaling a bearish trend. The ETF faces headwinds from lower oil prices and a strong US dollar, though long-term growth prospects remain tied to rising electricity demand from data centers and AI. Recent news highlights both opportunities in the energy transition and risks from regulatory delays and geopolitical tensions affecting solar investments.
The outlook for TAN is cautious near-term due to technical deterioration and valuation concerns, but sustained demand for clean energy offers long-term potential. Key risks include policy uncertainty, competition from nuclear energy, and reliance on large-scale solar projects. Investors should weigh volatility against the structural shift toward renewable infrastructure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Invesco Solar ETF
TAN is a thematic ETF that tracks the MAC Global Solar Energy Index. It provides targeted exposure to the global solar industry, including manufacturers of solar panels, installers, and component suppliers like Enphase and First Solar.
Read more on TAN →
